These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Daratumumab plus RVd for newly diagnosed multiple myeloma: final analysis of the safety run-in cohort of GRIFFIN. Voorhees PM; Rodriguez C; Reeves B; Nathwani N; Costa LJ; Lutska Y; Bobba P; Hoehn D; Pei H; Ukropec J; Qi M; Lin TS; Richardson PG Blood Adv; 2021 Feb; 5(4):1092-1096. PubMed ID: 33606004 [TBL] [Abstract][Full Text] [Related]
32. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting. Chari A; Parikh K; Ni Q; Abouzaid S Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207 [TBL] [Abstract][Full Text] [Related]
33. Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta-analysis. Xu W; Li D; Sun Y; Ran X; Wang B; Wu W; Sheng Z; Liu L Eur J Haematol; 2019 Dec; 103(6):542-551. PubMed ID: 31444819 [TBL] [Abstract][Full Text] [Related]
34. Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study. Yimer H; Melear J; Faber E; Bensinger WI; Burke JM; Narang M; Stevens D; Gray KS; Lutska Y; Bobba P; Qi K; Hoehn D; Qi M; Lin TS; Rifkin RM Leuk Lymphoma; 2022 Oct; 63(10):2383-2392. PubMed ID: 35730586 [TBL] [Abstract][Full Text] [Related]
35. Daratumumab, lenalidomide, and dexamethasone in Japanese patients with transplant-ineligible newly diagnosed multiple myeloma: a phase 1b study. Takamatsu H; Iida S; Shibayama H; Shibayama K; Yamazaki H; Suzuki K Int J Hematol; 2020 May; 111(5):692-701. PubMed ID: 32002821 [TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety analysis of bortezomib-based triplet regimens sequential lenalidomide in newly diagnosed multiple myeloma patients. Zhou Q; Xu F; Wen J; Yue J; Zhang Y; Su J; Liu Y Clin Exp Med; 2023 Sep; 23(5):1573-1580. PubMed ID: 36094683 [TBL] [Abstract][Full Text] [Related]
38. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221 [TBL] [Abstract][Full Text] [Related]
39. Comparisons of efficacy between frontline treatment with bortezomib-melphalan-prednisone and lenalidomide-dexamethasone for transplant-ineligible multiple myeloma: a multicenter real-world based registry report, CAREMM-2102 study. Lee JY; Park SS; Jeon YW; Shin SH; Yahng SA; Min CK; J Cancer Res Clin Oncol; 2023 Oct; 149(13):11907-11918. PubMed ID: 37418057 [TBL] [Abstract][Full Text] [Related]
40. Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma. Joseph NS; Kaufman JL; Dhodapkar MV; Hofmeister CC; Almaula DK; Heffner LT; Gupta VA; Boise LH; Lonial S; Nooka AK J Clin Oncol; 2020 Jun; 38(17):1928-1937. PubMed ID: 32298201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]